CRBP today
$4.00+$0.07 (+1.78%)close Nov 11, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bearish
1 hourBearish
15 minStrong Bearish
5 minStrong Bearish
Daily trend turns up above $4.34
Key levels
Resistance$4.93
Resistance$4.34
Support$3.87
Support$2.81
Latest news & SEC filings
AnalystMizuho keeps Outperform rating on Corbus Pharmaceuticals, cuts price target to $23
AnalystRBC Capital keeps Outperform on Corbus Pharmaceuticals, cuts target to $33
AnalystWedbush keeps Outperform rating on Corbus Pharmaceuticals, cuts target to $27
All CRBP news →About Corbus Pharmaceuticals
Corbus Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies for cancer and obesity. Its lead candidates are CRB-701, an antibody-drug conjugate targeting Nectin-4 for solid tumors, and CRB-913, an oral CB1 receptor inverse agonist for obesity. The company operates in the United States and Europe, relying on third-party manufacturers and licensing partners.
Based on the company's 10-K filed Mar 9, 2026.
Nasdaq · Healthcare
Corbus Pharmaceuticals Holdings, Inc. (CRBP)
What Is the Price Target for CRBP?
SEPT Low Target
$30.00
SEPT Mid Target
$31.50
SEPT High Target
$33.00
Analyst Consensus
$31.50
Is CRBP a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for CRBP.
Start Free Trial →Is CRBP Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$27.04
12
Moat Score
NONE
1/9
Piotroski Score
-4.1
Altman Z-Score
What Is Smart Money Doing with CRBP?
Insider Signal
SELLING
2 buys / 9 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
MEDIUM
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Kung Winston | director | Sale | 2,026 | $16K | Jun 10, 2026 |
| Jenkins John Kenneth | director | Sale | 4,800 | $38K | Jun 10, 2026 |
| Altmeyer Anne | director | Sale | 2,412 | $19K | Jun 10, 2026 |
| Saxena Nishant C | officer | Buy | 9,000 | $68K | Jun 3, 2026 |
| Saxena Nishant C | officer | Buy | 4,500 | $33K | Jun 2, 2026 |
| Saxena Nishant C | officer | Buy | 58,300 | - | May 21, 2026 |
| Kung Winston | director | Buy | 3,800 | - | May 19, 2026 |
| Jacques Rachelle Suzanne | director | Buy | 3,800 | - | May 19, 2026 |
| Jenkins John Kenneth | director | Buy | 3,800 | - | May 19, 2026 |
| Altmeyer Anne | director | Buy | 3,800 | - | May 19, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →CRBP Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
-60.33%
FCF Growth YoY
-54.3%
Revenue Trend
UNKNOWN
Dark Pool Trades for CRBP
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for CRBP, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 12:00:10 | $3.89 | 1,000 | $$4K | BUY |
| 24:11:38 | $4.03 | 1,000 | $$4K | SELL |
| 21:43:48 | $4.15 | 2,000 | $$8K | BUY |
| 21:26:04 | $4.00 | 16,799 | $$67K | SELL |
| 21:00:06 | $4.00 | 1,133 | $$5K | SELL |
5 dark pool trades shown · $$88K preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for CRBP
PREVIEWSEPT Investing provides real-time options flow tracking for CRBP, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $10 | Dec 18 | 37 | $$10 | 2 | SWEEP |
| CALL | $10 | Dec 18 | 37 | $$16 | 8 | SWEEP |
| CALL | $10 | Dec 18 | 37 | $$30 | 6 | SWEEP |
3 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Corbus Pharmaceuticals Holdings, Inc. (CRBP) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (0 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →CRBP — frequently asked questions
What is CRBP stock price today?
Corbus Pharmaceuticals Holdings, Inc. (CRBP) is at $4.00, up 1.78% (+$0.07) at the Nov 11, 2026 close.
Why is CRBP stock moving today?
Latest CRBP news — Nov 12, 2026: Mizuho keeps Outperform rating on Corbus Pharmaceuticals, cuts price target to $23 · Nov 11, 2026: RBC Capital keeps Outperform on Corbus Pharmaceuticals, cuts target to $33
What is the CRBP price target?
The average analyst price target for CRBP is $31.50, ranging from $30 to $33, based on 2 analysts. Latest: Wedbush maintains on May 27, 2026.
What do analysts rate CRBP?
Analyst ratings for CRBP: 0 Buy, 10 Hold, 0 Sell — consensus Hold.
Did CRBP beat earnings?
CRBP last reported on Aug 6, 2026: EPS -$1.81 vs -$1.26 expected — a miss of 43.7%.
Does CRBP pay a dividend?
CRBP does not currently pay a dividend.
What are CRBP support and resistance levels?
Support: $3.87, $2.81, $2.11. Resistance: $4.34, $4.93, $5.65.
What are insiders doing with CRBP?
Insider activity: SELLING, 2 buys and 9 sells in the last 90 days.
What is the latest news on CRBP?
Nov 12, 2026: Mizuho keeps Outperform rating on Corbus Pharmaceuticals, cuts price target to $23 · Nov 11, 2026: RBC Capital keeps Outperform on Corbus Pharmaceuticals, cuts target to $33 · Nov 11, 2026: Wedbush keeps Outperform rating on Corbus Pharmaceuticals, cuts target to $27